The ongoing recognition of several stereotyped combinations of B-cell receptor (BCR), sometimes associated with different prognosis, is gradually shifting the interest of BCR studies from a mere quantitative evaluation of IGHV gene mutational load toward a more complex identification of specific qualitative features of BCR. These include the characterization of IGHV-D-J rearrangements and the association with specific IGK/L chains, which may have, along with pathogenetic implications, both prognostic and therapeutic relevance. 7 The example reported here on SEPT10 expression in CLL mandates the need to integrate studies of novel surrogates for IGHV gene status, whose discovery is nowadays favored by the application of powerful techniques like microarrays, with investigations focusing on their clinical value also in the context of specific IGHV genes. As righteously underscored by Bilban et al., only few of the genes discovered by GEP, namely ZAP-70, have been so far validated for clinical use. 1,8 In this regard, it is mandatory that this validation includes, along with the correlation with IGHV gene mutational status, the demonstration of its independent clinical value in refining the prognostic assessment of CLL patients. 
In terms of tumorigenesis, it has been described that Ptc, a gene encoding a protein as the receptor of Shh, behaves as a tumor Abbreviations: AML, acute myeloblastic leukemia other than APL; APL, acute promyelocytic leukemia; B-ALL, B-cell acute lymphoblastic leukemia; B-CLL, B-cell chronic lymphocytic leukemia; MM, multiple myeloma; NA, not available; NK, natural killer cell lymphoma with bone marrow involvement; T-ALL, T-cell acute lymphoblastic leukemia; WM, Waldenstrongs macroglobulinemia.
The results are expressed as number of positive cases/number of total examined cases.
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Gli genes are oncogenic. 3 Medulloblastoma and basal cell carcinoma are malignancies most associated with the hedgehog pathway. In addition, Shh pathway has also been reported to play an important role in the malignant potential of small cell lung cancer and cancers of stomach, esophagus, pancreas, biliary tract, prostate gland and human intestinal stromal tumors. 3 Some studies have demonstrated an important role for Shh pathway in the regulation of proliferation of primitive human hematopoietic cells, 4 in early lymphoid cell differentiation 5 and in cytokine production and promoting cell cycle progression in Figure 1 Examples of immunohistochemical study. The immunohistochemical staining for a patient of acute myeloblastic leukemia (a, positive staining of Shh, Â 400; b, positive staining of Gli1, Â 400), a patient of multiple myeloma (c, positive staining of Shh, Â 400; d, positive staining of Gli1, Â 400), and a patient of T-cell acute lymphoblastic leukemia (e, negative staining of Shh, Â 400; f, negative staining of Gli1, Â 400).
Letters to the Editor activated peripheral CD4 þ T lymphocytes. 6 þ cell populations. There are evidences suggesting a role for Shh pathway in early lymphoid cell development and differentiation. 5 Shh pathway also plays a role in cytokine production and in promoting cell cycle progression in activated peripheral CD4
þ T lymphocytes. 6 With regards to B lymphocyte, Sacedon et al. 7 found that Shh produced by follicular dendritic cells could protect the survival and function of germinal center B cells. Detmer et al. 8 suggested that the hedgehog signaling pathway was involved in the control of hematopoietic differentiation, especially in erythropoiesis. Albeit evidences suggesting the implication of Shh pathway in the hematopoiesis and immune system, there is little evidence to demonstrate its relation to hematological malignancy.
Recently, we have analyzed if Shh and its downstream signaling Gli1 were expressed in patients and cell lines of hematological malignancies by immunohistochemical study. Primary antibodies for Shh (sc-9024 rabbit anti-Shh, H160) and for Gli1 (sc-20687 rabbit anti-Gli1, H300) were obtained from Santa Cruz. The immunohistochemical stain of Shh and Gli1 were performed on the bone marrow smear. There were 45 consecutive patients with newly diagnosed hematological malignancies at China Medical University Hospital in Taiwan between September 2005 and March 2007, including one patient of nasal natural killer cell lymphoma with extensive bone marrow involvement (Table 1) . Patients with acute promyelocytic leukemia (APL) had the highest frequency of positive staining both for Shh and Gli1 (100%). Nine (45%) and seven (35%) patients with acute myeloblastic leukemia other than APL (AML) were positive for Shh and Gli1, respectively. Concordant expression of Shh and Gli1 was in two myeloma patients (33%). All of the acute lymphoblastic and chronic lymphocytic leukemia were negative for both Shh and Gli1.
In addition, we examined the immunohistochemical study on six hematological cell lines: one AML cell line (KG-1), one APL cell line (HL-60), one B-cell ALL (B-ALL) cell line (Ramos), one T-cell ALL (T-ALL) cell line (Jurkat) and two multiple myeloma cell lines (U266 and ARH-77). Positive-Gli1 staining was found in HL-60 and the two myeloma cell lines (Table 1 ). These cells also stained weakly for Shh. Examples of immunohistochemical staining are shown in Figure 1 .
Till now, there are few studies addressing the implication of Shh signaling pathway in hematological malignancies. In the present study, we demonstrate the Shh and Gli1 proteins expression in some hematological malignancies, especially myeloid leukemia and multiple myeloma. It suggests a role for Shh signaling pathway in malignant potential of hematological malignancies. More detailed molecular descriptions of the function and localization of all Shh signaling proteins will aid in clarifying them. Nevertheless, tumorigenesis and prognosis prediction of Shh pathway in hematological malignancies remain for further examination.
